Transcriptional reprogramming triggered by neonatal UV radiation or Lkb1 loss prevents BRAFV600E-induced growth arrest in melanocytes

Altres autors/es

Institut Català de la Salut

[McGrail K, Granado-Martínez P, Orsenigo R, Recio JA] Grup de Recerca Biomèdica en Melanoma, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Caratù G, Nieto P, Heyn H] Single Cell Genomics Group at the Spanish National Centre for Genomic Analysis (CNAG), Barcelona, Spain. [Ferrer B, Hernández-Losa J] Servei d’Anatomia Patològica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Muñoz-Couselo E] Clinical Oncology Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [García-Patos V] Servei de Dermatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain

Vall d'Hebron Barcelona Hospital Campus

Data de publicació

2025-07-07T06:37:04Z

2025-07-07T06:37:04Z

2025-06-11



Resum

Transcriptional reprogramming; Neonatal UV radiation; Melanocytes


Reprogramació transcripcional; Radiació UV neonatal; Melanòcits


Reprogramación transcripcional; Radiación UV neonatal; Melanocitos


The mechanisms behind UVB-initiated, neonatal-specific melanoma linked to BRAFV600E are not well understood, particularly regarding its role in growth arrest. We found that, beyond mutations, neonatal UV irradiation or Lkb1 loss promotes a cell-autonomous transcriptional reprogramming that prevents BRAFV600E-induced growth arrest, leading to melanoma development. Using UVB-dependent and independent mouse models, genomic analyses, clinical data, and single-cell transcriptomics, we identified a transcriptional program that bypasses growth arrest, promoting melanoma. In humans, many of these genes are linked to poor survival and are upregulated in melanoma progression and other RAS pathway-driven tumors. Reconstitution experiments showed these genes cooperate with BRAFV600E in melanocyte transformation, dedifferentiation, and drug resistance. Depleting gene products like UPP1 highlights their potential as therapeutic targets. Our findings reveal that BRAFV600E-mutated melanomas can develop independently of nevus progression and identify novel targets for treatment.


This work was funded by Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF, “A way to make Europe”/“Investing in your future”), PI17/00043-Fondos FEDER; PI20/0384-Fondos FEDER; PI23/00428-Fondos FEDER JAR, Euronanomed2-ISCIII (AC16/00019)-Fondos FEDER; JAR, Asociación Española Contra el Cancer (AECC-GCB15152978SOEN). AGAUR, 2021-SGR00653 JAR (supported PGM, KM); Ramón Areces Foundation (supported KM and research); JAR. We thank Joan Seoane, HG Palmer, and FM Barriga for their critical comments.

Tipus de document

Article


Versió publicada

Llengua

Anglès

Publicat per

Springer Nature

Documents relacionats

Oncogene;44

https://doi.org/10.1038/s41388-025-03339-7

info:eu-repo/grantAgreement/ES/PE2017-2020/PI17%2F00043

info:eu-repo/grantAgreement/ES/PEICTI2021-2023/PI23%2F00428

Citació recomanada

Aquesta citació s'ha generat automàticament.

Drets

Attribution-NonCommercial-NoDerivatives 4.0 International

http://creativecommons.org/licenses/by-nc-nd/4.0/

Aquest element apareix en la col·lecció o col·leccions següent(s)